Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Items 301–400 of 1,000
BRMS1: a multifunctional signaling molecule in metastasis
Zimmermann, R. C., & Welch, D. R. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09871-0 · Cited by 51
“Studies have been done with HDAC inhibitors, but due to the universal function of those molecules, improved results have been limited [112].”
BackgroundAl‐Awadhi, F. H., Salvador‐Reyes, L. A., Elsadek, L. A., Ratnayake, R., Chen, Q.-Y., & Luesch, H. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00093 · Cited by 39
Mayr, C., Kiesslich, T., Erber, S., Bekric, D., Dobias, H., Beyreis, M., Ritter, M., Jäger, T., Neumayer, B., Winkelmann, P., et al. (2021) · Cancers · doi:10.3390/cancers13153862 · Cited by 34
“Moreover, HDAC class I enzymes are involved in DNA damage response, metastasis (by directly inhibiting the epithelial marker E-Cadherin), cell cycle progression, apoptosis resistance, and angiogenesis [6].”
BackgroundInfluentialMolecular Mechanisms and Epigenetic Regulation in Diabetic Cardiomyopathy
Mittal, A., Garg, R., Bahl, A., & Khullar, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.725532 · Cited by 34
Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
Wen, J., Chen, Y., Yang, J., Dai, C., Yu, S., Zhong, W., Liu, L., He, C., Zhang, W., Yang, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006857 · Cited by 34
Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells
Lo Cascio, C., McNamara, J. B., Melendez, E. L., Lewis, E. M., Dufault, M. E., Sanai, N., Plaisier, C. L., & Mehta, S. (2021) · JCI Insight · doi:10.1172/jci.insight.149232 · Cited by 33
“Discussion Considering the role of HDACs in oncogenesis, there has been an increased interest in testing HDACi for several malignancies, including both adult and pediatric gliomas (7, 59).”
BackgroundThe Effectiveness of Various Chemotherapeutic Agents in Cancer Treatment
Fathima, J. K., LAVANYA, V. A., Jamal, S., & Ahmed, N. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-022-00289-6 · Cited by 36
Butyrate as a Potential Modulator in Gynecological Disease Progression
Kim, N., & Yang, C. (2024) · Nutrients · doi:10.3390/nu16234196 · Cited by 41
Schizas, D., Mastoraki, A. T., Naar, L., Tsilimigras, D. I., Katsaros, I., Fragkiadaki, V., Karachaliou, G. S., Arkadopoulos, N. F., Liakakos, T., & Moris, D. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190712160842 · Cited by 36
Choi, M. A., Park, S. Y., Chae, H. Y., Song, Y., Sharma, C., & Seo, Y. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-49784-9 · Cited by 41
Lee, H., Chu, K., Moon, E., Kim, S. S., & Quan, F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.12.021 · Cited by 34
Integrated network analysis reveals new genes suggesting COVID-19 chronic effects and treatment
Pavel, A., del Giudice, G., Federico, A., Lieto, A. D., Kinaret, P., Serra, A., & Greco, D. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa417 · Cited by 37
“HDAC inhibitors are a class of compounds that act on epigenetic regulation of gene expression by increasing the lysine acetylation of histones [90].”
Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy
Ke, X., Lin, Z.-R., Ye, Z., Leng, M., Chen, B., Jiang, C., Jiang, X., & Li, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.679655 · Cited by 33
Demyanenko, S. V., & Sharifulina, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157947 · Cited by 34
Senescent cells and SASP in cancer microenvironment: New approaches in cancer therapy
Özdemir, A., Demir, Y. D. Ş., Yeşilyurt, Z. E., & Ark, M. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.10.002 · Cited by 37
Ouyang, B., Chen, D., Hou, X., Wang, T., Wang, J., Zou, W., Song, Z., Huang, C., Guo, Q., & Weng, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00346 · Cited by 37
Stitzlein, L. M., Adams, J. T., Stitzlein, E., Dudley, R. W., & Chandra, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02923-7 · Cited by 35
“In cancer treatment, HDAC inhibitors are used to induce cell cycle arrest and cell death by increasing gene transcription, such genes involved in both intrinsic, BAX, BAK, APAF1 , and extrinsic, TRAIL, DR5, FAS, FAS-L , and TNF-α , apoptotic pathways [80].”
BackgroundSirtuin 1 and oral cancer (Review)
Islam, S., Abiko, Y., Uehara, O., & Chiba, I. (2018) · Oncology Letters · doi:10.3892/ol.2018.9722 · Cited by 38
Zhang, L., Shan, X., Chen, Q., Xu, D., Fan, X., Yu, M., Yan, Q., & Liu, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28788 · Cited by 35
“…as entinostat(MS‐275); (d) cyclic tetrapeptides including FK228 and romidepsin; and (e) sirtuin inhibitors including the pan‐inhibitor (nicotinamide) and the specific SIRT inhibitors (sirtinol and cambinol; Bassett & Barnett, 2014; Ecks- chlager et al., 2017; Lane & Chabner, 2009; Reimer, 2015).”
BackgroundNanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
Tu, B., Zhang, M., Liu, T., & Huang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00400 · Cited by 32
HDAC3i‐Finder: A Machine Learning‐based Computational Tool to Screen for HDAC3 Inhibitors
Li, S., Ding, Y., Chen, M., Chen, Y., Kirchmair, J., Zhu, Z., Wu, S., & Xia, J. (2020) · Molecular Informatics · doi:10.1002/minf.202000105 · Cited by 33
The Anticancer Activity of Indazole Compounds: A Mini Review
Shang, C., Hou, Y., Meng, T., Shi, M., & Cui, G. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620999201124154231 · Cited by 32
Sheikhi, M., Ahmadi, Y., Kaviani, S., & Shаhаb, S. (2021) · Structural Chemistry · doi:10.1007/s11224-020-01697-4 · Cited by 33
Ramaiah, M. J., Kurappalli, R. K., Ramalingam, P. S., & Moparthi, N. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120024 · Cited by 34
Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs)
Baker, I. M., Smalley, J. P., Sabat, K. A., Hodgkinson, J. T., & Cowley, S. M. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00288 · Cited by 32
Katona, B. W., Glynn, R. A., Paulosky, K. E., Feng, Z., Davis, C. I., Ma, J., Berry, C. T., Szigety, K. M., Matkar, S. S., Liu, Y., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2133 · Cited by 33
Jiang, H., Patil, K., Vashi, A. P., Wang, Y., Strickland, E., & Pai, S. B. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100271 · Cited by 36
Li, A. M., & Ye, J. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-120857 · Cited by 36
RNA-modifying enzymes and their function in a chromatin context
Tzelepis, K., Rausch, O., & Kouzarides, T. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0312-0 · Cited by 32
Asa’ad, F., Monje, A., & Larsson, L. (2019) · European Journal Of Oral Sciences · doi:10.1111/eos.12657 · Cited by 32
Epigenetics and cell cycle regulation in cystogenesis
Li, X. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109509 · Cited by 33
Natural products development under epigenetic modulation in fungi
Li, C., Chung, Y., Wu, Y., Hunyadi, A., Wang, C. C. C., & Chang, F. (2020) · Phytochemistry Reviews · doi:10.1007/s11101-020-09684-7 · Cited by 33
“Mocetinostat is a selective inhibitor for classes I and IV HDACs.”
BackgroundInfluentialVisible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy
Josa‐Culleré, L., & Llebaria, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01713 · Cited by 33
“22,23 These enzymes remove acetyl groups from the amino-terminal lysine residues on histone tails and nonhistone proteins.”
Phthalimides Represent a Promising Scaffold for Multi‐Targeted Anticancer Agents
Matore, B. W., Banjare, P., Sarthi, A. S., Roy, P. P., & Singh, J. (2023) · ChemistrySelect · doi:10.1002/slct.202204851 · Cited by 33
HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury
Xie, M., Tang, Y., & Hill, J. A. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.02.013 · Cited by 31
“The HDAC inhibitors vorinostat, romidepsin, and belinostat have been approved for certain Tcell lymphomas, and panobinostat is approved for multiple myeloma; many more are in preclinical or phase II and III clinical trials (summarized in [18]).”
BackgroundInfluentialPerturbing Enhancer Activity in Cancer Therapy
Hamdan, F. H., & Johnsen, S. A. (2019) · Cancers · doi:10.3390/cancers11050634 · Cited by 34
“Multiple HDAC inhibitors have been approved by the United States Food and Drug Administration (FDA) for use in indications such as relapsed and refractory cutaneous T-cell lymphoma, peripheral T cell lymphoma, and multiple myeloma [165].”
BackgroundEpigenetic mechanisms involved in hepatocellular carcinoma development and progression
Bueloni, B., Fernández‐Barrena, M. G., Avila, M. A., Bayo, J., & Mazzolini, G. D. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100186 · Cited by 36
“These enzymes are categorised into two major groups: GNAT (including HAT1, General Control Non-repressed protein 5 (GCN5), P300/CBP-associated factor (PCAF)) and MYST (comprising Tip60, 21 The addition of negatively charged acetyl groups neutra-lises the positive charge of lysines, weakening the interaction between nu…”
He, Y., Chen, D., Yi, Y., Zeng, S., Liu, S., Li, P., Xie, H., Yu, P. Y., Jiang, G., & Liu, H. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.05.001 · Cited by 33
“HDAC inhibitors (HDACis) decrease HDAC activity and exert suppressive effects against various tumor cells via inhibiting cell proliferation and inducing cell cycle arrest and apoptosis.(9,10) Therefore, HDACis are considered as a promising novel therapeutic approach in the light of their potent tumor-selective effects…”
BackgroundHDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice
Afaloniati, H., Angelopoulou, K., Giakoustidis, A. E., Hardas, A., Pseftogas, A., Makedou, K., Gargavanis, A. A., Goulopoulos, T., Iliadis, S., Papadopoulos, V. N., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s250233 · Cited by 30
Olaoye, O. O., Watson, P. R., Nawar, N., Geletu, M., Sedighi, A., Bukhari, S., Raouf, Y. S., Manaswiyoungkul, P., Erdogan, F., Abdeldayem, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01922 · Cited by 31
Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer
Lin, C., Huang, K., Lin, Y., Yang, S., Chung, W.-C., Chang, Y., Shih, J., Ho, C., Lin, C.-A., Shih, C.-C., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.022 · Cited by 33
Ovejero-Sánchez, M., González‐Sarmiento, R., & Herrero, A. B. (2021) · Neoplasia · doi:10.1016/j.neo.2021.04.003 · Cited by 31
Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease
Cai, Q., Gan, C., Tang, C., Wu, H. M., & Gao, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.784591 · Cited by 32
“However, because of the non-significant efficacy and the certain toxic and side effects, these drugs are generally used in combination with other chemotherapy drugs (Eckschlager et al., 2017; Takebe et al., 2019; Shetty et al., 2021).”
BackgroundAdoptive tumor infiltrating lymphocytes cell therapy for cervical cancer
Zhu, Y., Zhou, J., Zhu, L., Hu, W., Liu, B., & Xie, L. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2060019 · Cited by 31
“cell death in cancer cells, reduce angiogenesis, and modulate the immune response.(88) It converted cancer cells into sensitive cells susceptive to immunotherapy by raising expression levels of tumor antigen.”
BackgroundTherapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells
Lin, P., Hsieh, H.-Y., Chu, P., & Chen, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071939 · Cited by 32
Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment “jigsaw puzzle”
Dzobo, K. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0206 · Cited by 29
“Well-known FDA-approved HDAC inhibitors include belinostat (Spectrum Pharmaceuticals), vorinostat (Merck and Co.), and romidepsin (Celgene) (Eckschlager et al., 2017; Lee et al., 2015).”
Huang, W. J., Zeng, C., Liu, J., Yuan, L., Liu, W., Wang, L., Zhu, H., Yang, X., Luo, Y., Xie, D., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.111 · Cited by 32
HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells
Chen, S., Chow, J., Hsieh, Y., Lin, C., Hsu, K., Hsieh, W.-S., Chi, W.-M., Shabangu, B. M., & Lee, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092271 · Cited by 30
“Histone acetyl tion has been shown to b an important regul tory mechanism that controls trans ription of approximately 2%–10% of genes [4].”
BackgroundInfluentialSachan, R., Dey, P. K., Park, C., Yang, J., Son, J. Y., Park, J. H., Lee, S. H., Ahn, M., Kim, I. S., Moon, H. R., et al. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2019.074 · Cited by 30
“Pracinostat belongs to a class of hydroxamic acids that specifically target HDAC class I, II, and IV, and is currently in phase II of clinical trials for the treatment of prostate cancer patients (Ganai, 2016; Eckschlager et al., 2017).”
BackgroundElek, G. Z., Koppel, K., Zubrytski, D. M., Konrad, N., Järving, I., Lopp, M., & Kananovich, D. G. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b03305 · Cited by 32
The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy
Psilopatis, I., Garmpis, N., Garmpi, A., Vrettou, K., Sarantis, P., Koustas, E., Antoniou, E., Dimitroulis, D., Kouraklis, G. P., Karamouzis, M. V., et al. (2023) · Cancers · doi:10.3390/cancers15082222 · Cited by 32
“So far, only a few HDACIs have, however, received Food and Drug Administration (FDA) approval for T-cell lymphoma or multiple myeloma [31,32].”
BackgroundMehrpouri, M., Safaroghli‐Azar, A., Pourbagheri‐Sigaroodi, A., Momeny, M., & Bashash, D. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173050 · Cited by 29
Lin, Y., Yao, M., Wu, H., Dong, J. P., Ni, H., Kou, X., Chang, L., Luo, C., & Zhu, D. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15043 · Cited by 31
Hoffmann, M. J., Meneceur, S., Hommel, K., Schulz, W. A., & Niegisch, G. (2021) · Genes · doi:10.3390/genes12020260 · Cited by 28
The pharmacoepigenetic paradigm in cancer treatment
Ocaña-Paredes, B., Rivera-Orellana, S., Ramírez-Sánchez, D., Montalvo-Guerrero, J., Freire, M. P., Espinoza-Ferrao, S., Altamirano-Colina, A., Echeverría-Espinoza, P., Ramos-Medina, M. J., Echeverría‐Garcés, G., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1381168 · Cited by 29
“Histone deacetylase inhibitors are essential chemotherapeutic agents used in cancer therapy, serving as both cytotoxic and cytostatic drugs (Ferrarelli, 2016; Eckschlager et al., 2017) (Figure 1).”
BackgroundNatarajan, U., Venkatesan, T., Radhakrishnan, V., Samuel, S., Rasappan, P., & Rathinavelu, A. (2019) · Medicina · doi:10.3390/medicina55020030 · Cited by 30
“In fact, when HDAC inhibitors are combined with other inhibitors, including blockers of DNA methyl transferases, it was reported that the combination increased antitumor effects on myelodysplastic syndrome and prostate, ovarian, and pancreatic endocrine tumor cells, suggesting superior benefits for carefully selected…”
BackgroundTargeting Cancer through the Epigenetic Features of Telomeric Regions
Vaquero-Sedas, M. I., & Vega-Palas, M. A. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.12.006 · Cited by 30
HDAC inhibitors rescue multiple disease-causing CFTR variants
Anglès, F., Hutt, D. M., & Balch, W. E. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz026 · Cited by 28
Nitika, N., Blackman, J. S., Knighton, L. E., Takakuwa, J. E., Calderwood, S. K., & Truman, A. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-70764-x · Cited by 28
Histone deacetylase in neuropathology
Gupta, R. V., Ambasta, R. K., & Kumar, P. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.09.004 · Cited by 33
The Epigenetics of Glioma Stem Cells: A Brief Overview
Valor, L. M., & Hervás-Corpión, I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.602378 · Cited by 28
“Inhibition of HDACs can induce cell cycle arrest, apoptosis and cellular differentiation and can interfere with cancer angiogenesis (68).”
BackgroundTargeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
Okabe, S., Tanaka, Y., & Gotoh, A. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00213-6 · Cited by 29
“Expression of HDAC in myeloma cells HDACs are essential for transcriptional gene activity [6].”
BackgroundChen, Q., Wang, Y., Jiao, F., Cao, P., Shi, C., Pei, M., Wang, L., & Gong, Z. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16751 · Cited by 29
Marx, C., Sonnemann, J., Beyer, M., Maddocks, O. D. K., Lilla, S., Hauzenberger, I., Piée‐Staffa, A., Siniuk, K., Nunna, S., Marx-Blümel, L., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13060 · Cited by 30
Gordon, M. S., Shapiro, G. I., Sarantopoulos, J., Juric, D., Lu, B., Zarotiadou, A., Connarn, J. N., Bruchec, Y. L., Dumitru, C. D., & Harvey, R. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.786120 · Cited by 31
“Histone deacetylases (HDACs) are commonly overexpressed in many types of cancers (1, 2), an observation that has led to the emergence of cancer therapies targeting HDACs (3).”
BackgroundLiang, H., Xiong, Z., Li, R., Hu, K., Cao, M., Yang, J., Zhong, Z., Jia, C., Yao, Z., & Deng, M. (2019) · Journal of Cancer · doi:10.7150/jca.32022 · Cited by 32
“progression and that histone deacetylase inhibitors acted as therapeutic strategies for cancer [34, 35].”
BackgroundNovel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer
Shackleton, E. G., Ali, H. Y., Khan, M. A., Pockley, A. G., & McArdle, S. (2021) · Cancers · doi:10.3390/cancers13051145 · Cited by 31
Wu, H., & Chu, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158113 · Cited by 35
Targeting Histone Modifications in Bone and Lung Metastatic Cancers
Edwards, C. M., & Johnson, R. W. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00670-2 · Cited by 35
Phytochemicals as Epigenetic Modulators in Chronic Diseases: Molecular Mechanisms
Cord, D., Rîmbu, M. C., Iordache, M. P., Albulescu, R., Pop, S., Tănase, C., & Popa, M.-L. (2025) · Molecules · doi:10.3390/molecules30214317 · Cited by 35
Cardoso, A. R., Lobo, J., Miranda‐Gonçalves, V., Henrique, R., & Jerónimo, C. (2020) · Epigenetics · doi:10.1080/15592294.2020.1805682 · Cited by 31
“A study combined hydralazine, a drug used for treating hypertension and repurposed for its action as weak non-nucleoside DNMTi (demonstrated by us and others [45]), and magnesium valproate, a histone deacetylase inhibitor (HDACi) [46].”
BackgroundInfluentialWatt, R., Parkin, K., & Martino, D. (2020) · Challenges · doi:10.3390/challe11020025 · Cited by 29
“Conventional HDAC inhibitors are clinically approved for the treatment of cancer and have been found to induce cell cycle arrest, differentiation, cell death and reduced angiogenesis in tumours [58,59].”
Role of long non‑coding RNAs and related epigenetic mechanisms in liver fibrosis (Review)
Ganguly, N., & Chakrabarti, S. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4856 · Cited by 30
Upadhyay, N., Tilekar, K. N., Safuan, S., Kumar, A. P., Schweipert, M., Meyer‐Almes, F., & Ramaa, C. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00125f · Cited by 30
Ramaiah, M. J., Ramalingam, P. S., Mathavan, S., Yamajala, R. B. R. D., Moparthi, N. R., Kurappalli, R. K., & Manyam, R. R. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109876 · Cited by 29
Iyer, S. P., Huen, A., Ai, W. Z., Jagadeesh, D., Lechowicz, M. J., Okada, C. Y., Feldman, T. A., Ghione, P., Alderuccio, J. P., Champion, R., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.281875 · Cited by 41
“26 Romidepsin, is used to treat PTCL and CTCL in patients who have received at least one prior therapy.”
BackgroundExpression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma
Shao, Y., Liu, Z., Liu, J., Wang, H., Huang, L., Lin, T., Liu, J., Wei, Q., Zeng, H., He, G., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4603 · Cited by 34
“As a HDACI, TSA is known to reverse the deacetylated status of histones (43), which could possibly play a role in the mechanisms described above.”
BackgroundHamajima, W., Fujimura, A., Fujiwara, Y., Yamatsugu, K., Kawashima, S. A., & Kanai, M. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00102 · Cited by 27
Park, S., Joo, S. H., Lee, N., Jang, W., Seo, J. H., & Jeong, C. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01359-x · Cited by 29
“HDAC inhibitors regulate the expression of various genes by modulating the acetylation states of histone protein (Eckschlager et al. 2017).”
BackgroundJiang, X., Jiang, L., Cheng, J., Chen, F., Ni, J., Yin, C., Wang, Q., Wang, Z., Fang, D. H., Yi, Z., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02789-3 · Cited by 33
Huang, F.-I., Wu, Y.-W., Sung, T.-Y., Liou, J., Lin, M., Pan, S., & Yang, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00249 · Cited by 27
“For example, SAHA, PXD101, and LBH589 have been approved for the treatment of cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and MM, respectively (36).”
BackgroundPotluri, V., Shandil, R., Gavara, R., Sambasivam, G., Campo, B., Wittlin, S., & Narayanan, S. (2020) · Malaria Journal · doi:10.1186/s12936-020-03421-3 · Cited by 24
An Overview of Autophagy in Helicobacter pylori Infection and Related Gastric Cancer
Yang, Y., Shu, X., & Xie, C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.847716 · Cited by 32
Blake, M. K., O’Connell, P. M., & Aldhamen, Y. A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1082195 · Cited by 29
“For example, selective HDAC6 inhibition with ACY-1215 and ACY-241 was efficacious towards melanoma patients’ T cells ex-vivo, harvested from either peripheral blood or tumor biopsies (Laino et al., 2019).”
BackgroundResultInfluentialSmall-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy
Xie, X., Zhang, N., Li, X., Huang, H., Peng, C. Y., Huang, W., Foster, L. J., He, G., & Han, B. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106721 · Cited by 28
Lin, W. Y., Wang, X., Diao, M., Wang, Y., Zhao, R., Chen, J., Liao, Y., Long, Q., & Meng, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03418-x · Cited by 32
“Treating tumors with HDACis stimulates the generation of ROS, triggers the intrinsic pathway of apoptosis, and is linked to cell death [122, 123].”
BackgroundAkgün, O., Erkısa, M., & Arı, F. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28813 · Cited by 27
“Even today, many HDAC inhibitors are evaluated in phase I/II clinical trials (hematological and solid tumors) in combination with monotherapy or other therapeutic agents.(15) Valproic acid (VPA, 2‐propylpentanoic acid) is a Food and Drug Administration (FDA) approved drug for the long‐term treatment of epilepsy.”
BackgroundOsko, J. D., & Christianson, D. W. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.06.028 · Cited by 28
“The HDAC inhibitors Romidepsin, Vorinostat, Belinostat, and Panobinostat are currently approved for clinical use, and others are in various stages of clinical trials (Dokmanovic et al., 2007; West et al., 2014; Ma et al., 2016; Eckschlager et al., 2017).”
BackgroundKonarzewska, Z., Śliwińska‐Wilczewska, S., Barreiro, A., Vasconcelos, V. M., & Latała, A. (2020) · Marine Drugs · doi:10.3390/md18040179 · Cited by 26
“[41] have proven that silanediols represent a novel zinc binding group (ZBG) with properties that can be used for the development of histone deacetylase inhibitors, which have an important role inter alia in apoptosis [42].”
BackgroundMoita, A. J. R., Bandolik, J. J., Hansen, F. K., Kurz, T., Hamacher, A., & Kassack, M. U. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218300 · Cited by 26
“Another widely tested approach to address chemoresistance is epigenetic modulation [27,28].”
BackgroundUveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor
Sundaramurthi, H., García‐Mulero, S., Tonelotto, V., Slater, K., Marcone, S., Piulats, J. M., Watson, R. W. G., Tobin, D. J., Jensen, L. D., & Kennedy, B. N. (2022) · Cancers · doi:10.3390/cancers14030782 · Cited by 29
“Four pan-HDAC inhibitors—Vorinostat (SAHA) for relapsed and refractory cutaneous T-cell lymphoma (CTCL), Belinostat for peripheral T-cell lymphoma (PTCL), Romidepsin for CTCL/PTCL and Panobinostat for multiple myeloma – are approved for market use as treatment options by the FDA and/or EMA [18].”
BackgroundHDAC2 and 7 down-regulation induces senescence in dermal fibroblasts
Warnon, C., Bouhjar, K., Ninane, N., Verhoyen, M., Fattaccioli, A., Fransolet, M., Lambert de Rouvroit, C., Poumay, Y., Piel, G., Mottet, D., et al. (2021) · Aging · doi:10.18632/aging.203304 · Cited by 25
“In cancer cell lines and in normal fibroblasts, SAHA was shown to induce several senescence biomarkers such as growth arrest and an increased proportion of SA-βgal positive cells [18, 19].”
Bollmann, L. M., Skerhut, A. J., Asfaha, Y., Horstick‐Muche, N., Hanenberg, H., Hamacher, A., Kurz, T., & Kassack, M. U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113398 · Cited by 25
“Through epigenetic modulation, histone deacetylases (HDACs) have an impact on various cellular processes [15].”
BackgroundInfluentialMEF-2 isoforms' (A-D) roles in development and tumorigenesis
Madugula, K., Mulherkar, R., Khan, Z. K., Chigbu, D. I., Patel, D., Harhaj, E. W., & Jain, P. (2019) · Oncotarget · doi:10.18632/oncotarget.26763 · Cited by 27
“Sirtinol and Cambinol are drugs in the preclinical stage of investigation, and EX-527 is in phase I and II trial for Huntington’s disease and glaucoma [86].”
BackgroundSingh, V. K., Pal, R. R., Srivastava, P., Misra, G., Shukla, Y., & Sharma, P. K. (2021) · Environmental Pollution · doi:10.1016/j.envpol.2020.116397 · Cited by 26
Jaufmann, J., Franke, F. C., Sperlich, A., Blumendeller, C., Kloos, I., Schneider, B., Sasaki, D., Janssen, K., & Beer‐Hammer, S. (2021) · The FASEB Journal · doi:10.1096/fj.202002495r · Cited by 28
Lee, H., Chu, K., Moon, E., & Quan, F. (2021) · Journal of Cancer · doi:10.7150/jca.60027 · Cited by 27
“Additionally, several other HDACi including the panHDACi (givinostat, resminostat, bexinostat, and quisinostat) and class-specific selective HDACi (CHR-2996 for class I and rocilinostat for class II) are currently undergoing clinical trials [18].”
BackgroundRomanelli, M. N., Borgonetti, V., & Galeotti, N. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105901 · Cited by 25
Luo, G., Lin, X., Ren, S., Wu, S., Wang, X., Ma, L., & Xiang, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113870 · Cited by 25
PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen
Tinsley, S. L., & Allen-Petersen, B. L. (2022) · NAR Cancer · doi:10.1093/narcan/zcac002 · Cited by 26
“Intriguingly, HDAC inhibitors seem to function similarly, with cancer cells displaying a unique vulnerability to epigenetic-based therapeutics (178).”
Background
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
